1️⃣ Chiesi paid for an HAE launch, not a promise

Chiesi agreed to buy KalVista for $27 a share in cash, valuing the company at about $1.9B and giving Chiesi Ekterly, the oral on-demand HAE drug approved in 2025.

💡 Why it matters

This is rare-disease M&A with revenue already visible. The risk is less about biology and more about how much oral HAE share survives the next competitive wave.

☕ Coffee talk

If Ekterly is already off the board, who has to decide whether Pharvaris is next or just more expensive?


2️⃣ Avalyn found a real IPO window

Avalyn priced an upsized IPO at $18 a share, raising expected gross proceeds of $300M before its Nasdaq debut under AVLN on April 30.

💡 Why it matters

This is a useful market signal. Public buyers funded a Phase 2 respiratory biotech around inhaled reformulations, not a clean late-stage biologic or obesity story.

☕ Coffee talk

How many private respiratory companies just got a better comp because Avalyn cleared $300M?


3️⃣ GSK’s Alector bet lost its second leg

Alector will discontinue the Phase 2 PROGRESS-AD trial of nivisnebart after an interim futility analysis found it was unlikely to slow disease progression.

💡 Why it matters

The progranulin thesis now has two clinical misses inside the same GSK-backed collaboration. The question moves from target rationale to human translation.

☕ Coffee talk

After latozinemab and nivisnebart, who still wants to pay up for antibody-based neuroimmune biology before human proof?